Decoy Therapeutics, Inc. (NASDAQ: DCOY) corrected its September 22, 2026, announcement of a warrant inducement transaction with an existing institutional investor. The investor will immediately exercise 1,184,434 Series B Milestone Warrants issued on June 29, 2026, at $3.25 per share, generating approximately $3.85 million in gross proceeds before fees and expenses. Decoy will reduce the exercise prices of its outstanding Series A and Series C Milestone Warrants from $5.91 to $3.25 per share and issue unregistered warrants covering up to 2,368,868 common shares. The company clarified that the New Warrants are not subject to stockholder approval, will become exercisable immediately upon issuance and will expire five years from the issuance date. The transaction is expected to close on or about September 23, 2026, subject to customary conditions, with Curvature Securities LLC as sole placement agent. Decoy develops Designable Multi-Antivirals, or D-MAVs, using its IMP³ACT platform, which combines AI-assisted design and rapid synthesis.